Cargando…
Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139920/ https://www.ncbi.nlm.nih.gov/pubmed/37131960 http://dx.doi.org/10.1016/j.jvacx.2023.100307 |
| _version_ | 1785033052491087872 |
|---|---|
| author | Sáez-Llorens, Xavier Lanata, Claudio Aranguren, Elaine Celis, Carlos R. Cornejo, Rubelio DeAntonio, Rodrigo Ecker, Lucie Garrido, Diegi Gil, Ana I. Gonzales, Marina Hess-Holtz, Morgan Leroux-Roels, Geert Junker, Helga Kays, Sarah-Katharina Koch, Sven D. Lazzaro, Sandra Mann, Philipp Quintini, Gianluca Srivastava, Barkha Vahrenhorst, Dominik von Eisenhart-Rothe, Philipp Wolz, Olaf-Oliver Oostvogels, Lidia |
| author_facet | Sáez-Llorens, Xavier Lanata, Claudio Aranguren, Elaine Celis, Carlos R. Cornejo, Rubelio DeAntonio, Rodrigo Ecker, Lucie Garrido, Diegi Gil, Ana I. Gonzales, Marina Hess-Holtz, Morgan Leroux-Roels, Geert Junker, Helga Kays, Sarah-Katharina Koch, Sven D. Lazzaro, Sandra Mann, Philipp Quintini, Gianluca Srivastava, Barkha Vahrenhorst, Dominik von Eisenhart-Rothe, Philipp Wolz, Olaf-Oliver Oostvogels, Lidia |
| author_sort | Sáez-Llorens, Xavier |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10139920 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101399202023-04-28 Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] Sáez-Llorens, Xavier Lanata, Claudio Aranguren, Elaine Celis, Carlos R. Cornejo, Rubelio DeAntonio, Rodrigo Ecker, Lucie Garrido, Diegi Gil, Ana I. Gonzales, Marina Hess-Holtz, Morgan Leroux-Roels, Geert Junker, Helga Kays, Sarah-Katharina Koch, Sven D. Lazzaro, Sandra Mann, Philipp Quintini, Gianluca Srivastava, Barkha Vahrenhorst, Dominik von Eisenhart-Rothe, Philipp Wolz, Olaf-Oliver Oostvogels, Lidia Vaccine X Corrigendum Elsevier 2023-04-28 /pmc/articles/PMC10139920/ /pubmed/37131960 http://dx.doi.org/10.1016/j.jvacx.2023.100307 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Corrigendum Sáez-Llorens, Xavier Lanata, Claudio Aranguren, Elaine Celis, Carlos R. Cornejo, Rubelio DeAntonio, Rodrigo Ecker, Lucie Garrido, Diegi Gil, Ana I. Gonzales, Marina Hess-Holtz, Morgan Leroux-Roels, Geert Junker, Helga Kays, Sarah-Katharina Koch, Sven D. Lazzaro, Sandra Mann, Philipp Quintini, Gianluca Srivastava, Barkha Vahrenhorst, Dominik von Eisenhart-Rothe, Philipp Wolz, Olaf-Oliver Oostvogels, Lidia Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_full | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_fullStr | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_full_unstemmed | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_short | Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] |
| title_sort | corrigendum to “safety and immunogenicity of mrna-lnp covid-19 vaccine cvncov in latin american adults: a phase 2 randomized study” [vaccine: x 11 (2022) 100189] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139920/ https://www.ncbi.nlm.nih.gov/pubmed/37131960 http://dx.doi.org/10.1016/j.jvacx.2023.100307 |
| work_keys_str_mv | AT saezllorensxavier corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT lanataclaudio corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT arangurenelaine corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT celiscarlosr corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT cornejorubelio corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT deantoniorodrigo corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT eckerlucie corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT garridodiegi corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT gilanai corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT gonzalesmarina corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT hessholtzmorgan corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT lerouxroelsgeert corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT junkerhelga corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT kayssarahkatharina corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT kochsvend corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT lazzarosandra corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT mannphilipp corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT quintinigianluca corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT srivastavabarkha corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT vahrenhorstdominik corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT voneisenhartrothephilipp corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT wolzolafoliver corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 AT oostvogelslidia corrigendumtosafetyandimmunogenicityofmrnalnpcovid19vaccinecvncovinlatinamericanadultsaphase2randomizedstudyvaccinex112022100189 |